Oragenics, Inc. announced in July 2024 that its lead candidate, ONP-002, successfully demonstrated a strong cardiac safety margin. The drug cleared FDA-required cardiotoxicity tests, indicating it is unlikely to cause cardiac arrhythmias.
This milestone is crucial for de-risking the ONP-002 program as it advances towards Phase II clinical trials. Positive safety data is a fundamental requirement for regulatory approval and continued drug development.
The successful completion of these tests provides further confidence in the safety profile of ONP-002. This allows Oragenics to proceed with its clinical development plan for the concussion treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.